Initial interim data show favorable drug exposure and confirm ALG.APV-527 biological activityEarly promising signs of clinical activity in heavily pretreated…
NORTHAMPTON, MA / ACCESSWIRE / March 7, 2024 / Gilead SciencesFor many people living with cancer, hearing about the experiences…
PARIS, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the first commercial…
AIM CEO Corner AIM CEO Corner CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline…
BOSTON and ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical…
Company announces new partners including The University of Texas and Rising Pharmaceuticals FREDERICK, Md., March 07, 2024 (GLOBE NEWSWIRE) --…
Data support evaluation of the effects of two weeks of TNX-102 SL therapy on severity of acute stress reaction (ASR)…
Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer),…
Company maintains solid cash position of $158.9 millionSOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc.…
Five abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technologyDifferentiated preclinical activity for CAB anti-Nectin4-antibody drug…